Journal of Yeungnam Medical Science

Original articles

Clinical and histopathologic analysis of gynecological cancer: a single institute experience over 7 years: Soo-Young Lee, Eunbyeol Kim, Hyo-Shin Kim, Yu-Jin Koo, Dae-Hyung Lee; Yeungnam Univ J Med. 2020;37(3):179-185. Published online March 5, 2020; DOI: https://doi.org/10.12701/yujm.2019.00451

6,188 View
174 Download
2 Crossref

Background
Approximately 100,000 women are diagnosed with cancer each year in Korea. According to a survey by the Korean central cancer registry in 2016, uterine cervical cancer, uterine corpus cancer, and ovarian cancer were the 5th, 7th, and 8th most prevalent cancers respectively among Korean women. The present study aims to review the clinico-pathologic characteristics of patients who were treated for major gynecological malignancies at Yeungnam University Medical Center.
Methods
Patients with invasive gynecological cancers from January 2012 to February 2019 were retrospectively identified. We analyzed the clinical features, demographic profiles, pathologic data, treatment modality used, adjuvant treatment used, complications, recurrence, and survival outcomes.
Results
A total of 287 patients (cervical cancer 115; corporal cancer 86; and ovarian, tubal, or primary peritoneal cancer 90) were included. Most cervical (82.7%) and corporal cancers (89.5%) were diagnosed in the early stages (stage I or II), while more than half (58.9%) the cases of ovarian, tubal or peritoneal cancers were diagnosed in the advanced stages (stage III or IV). Surgical complications were observed in 12.2% of cervical cancers, 16.3% of uterine corpus cancers, and 11.1% of ovarian, tubal, and peritoneal cancers, respectively. The 5-year overall survival rate was 94.1%, 91.0%, and 77.1% for cervical, corporal, and ovarian, tubal, or peritoneal cancers, respectively.
Conclusion
Surgical treatment was satisfactory in terms of the incidence of complications, and survival outcomes were generally good. Clinicians should be aware of the clinical and histopathological characteristics of patients with gynecological cancers to be able to provide optimal strategies and counseling.

Citations

Citations to this article as recorded by

Molecular landscape of recurrent cervical cancer
Divya Adiga, Sangavi Eswaran, Deeksha Pandey, Krishna Sharan, Shama Prasada Kabekkodu
Critical Reviews in Oncology/Hematology.2021; 157: 103178. CrossRef
Histopathological Study of Gynecological Cancers in Patients Admitted to Baqiyatallah Hospital in Tehran during 2011-2019
Seyedeh Razieh Hashemi, Mohammad Reza Akbari, Zahra Soleimani
Avicenna Journal of Clinical Medicine.2021; 28(1): 42. CrossRef

Clinical significance of lymph node size in locally advanced cervical cancer treated with concurrent chemoradiotherapy: Jinju Oh, Ki Ho Seol, Youn Seok Choi, Jeong Won Lee, Jin Young Bae; Yeungnam Univ J Med. 2019;36(2):115-123. Published online February 21, 2019; DOI: https://doi.org/10.12701/yujm.2019.00143

7,462 View
98 Download
8 Crossref

Abstract PDF

Background
This study aimed to assess the in-field lymph node (LN) failure rate according to LN size and to investigate effect of LN size on the survival outcome of patients with locally advanced cervical carcinoma treated with concurrent chemoradiotherapy (CCRT).
Methods
A total of 310 patients with locally advanced cervical carcinoma treated with CCRT were enrolled in retrospective study. LN status was evaluated by magnetic resonance imaging. All patients received conventional external beam irradiation and high-dose rate brachytherapy, and concurrent cisplatin-based chemotherapy. In-field LN failure rate according to LN size was analyzed.
Results
The median follow-up period was 83 months (range, 3-201 months). In-field LN failure rate in patients with pelvic LN size more than 10 mm was significantly higher than that in patients with pelvic LN size less than 10 mm (p<0.001). A similar finding was observed in the in-field para-aortic LN failure rate (p=0.024). The pelvic and para-aortic LN size (≥10 mm) was a significant prognostic factor of overall-survival (OS) and disease-free survival rate in univariate and multivariate analyses. The OS rate was significantly different between groups according to LN size (<10 mm vs. ≥10 mm).
Conclusion
A LN of less than 10 mm in size in an imaging study is controlled by CCRT. On the other hand, in LN of more than 10 mm in size, the in-field LN failure rate increase and the prognosis deteriorate. Therefore, a more aggressive treatment strategy is needed.

Citations

Citations to this article as recorded by

Therapeutic effects of surgical debulking of metastatic lymph nodes in cervical cancer IIICr: a trial protocol for a phase III, multicenter, randomized controlled study (KGOG1047/DEBULK trial)
Bo Seong Yun, Kwang-Beom Lee, Keun Ho Lee, Ha Kyun Chang, Joo-Young Kim, Myong Cheol Lim, Chel Hun Choi, Hanbyoul Cho, Dae-Yeon Kim, Yun Hwan Kim, Joong Sub Choi, Chae Hyeong Lee, Jae-Weon Kim, Sang Wun Kim, Yong Bae Kim, Chi-Heum Cho, Dae Gy Hong, Yong J
Journal of Gynecologic Oncology.2024;[Epub] CrossRef
Can we triumph over locally advanced cervical cancer with colossal para-aortic lymph nodes? A case report
Abdulla Alzibdeh, Issa Mohamad, Lina Wahbeh, Ramiz Abuhijlih, Fawzi Abuhijla
World Journal of Clinical Cases.2024; 12(10): 1851. CrossRef
RECIST 1.1 versus clinico-radiological response assessment for locally advanced cervical cancer: implications on interpreting survival outcomes of future trials
Mayuri Charnalia, Supriya Chopra, Jaahid Mulani, Palak Popat, Sushmita Rath, Maarten Thomeer, Prachi Mittal, Ankita Gupta, Ingrid Boere, Sudeep Gupta, Remi A Nout
International Journal of Gynecologic Cancer.2024; : ijgc-2024-005336. CrossRef
Efficacy of lymph node dissection on stage IIICr of cervical cancer before CCRT: study protocol for a phase III, randomized controlled clinical trial (CQGOG0103)
Misi He, Mingfang Guo, Qi Zhou, Ying Tang, Lin Zhong, Qing Liu, Xiaomei Fan, Xiwa Zhao, Xiang Zhang, Gang Chen, Yuanming Shen, Qin Xu, Xiaojun Chen, Yuancheng Li, Dongling Zou
Journal of Gynecologic Oncology.2023;[Epub] CrossRef
Stadializarea clinică şi chirurgicală a pacientelor cu cancer de col uterin – studiu retrospectiv privind corelaţiile dintre diagnosticul iniţial, opţiunile de tratament şi rezultatele histopatologice
Mihai-Cristian Dumitraşcu, Adina-Elena Nenciu, Cătălin George Nenciu, Carmen Ursu, Andreea Ilieşiu, Alexandru Baroş, Diana Secară, Monica Mihaela Cîrstoiu
Ginecologia.ro.2023; 1(39): 30. CrossRef
Treatment of bulky lymph nodes in locally advanced cervical cancer: boosting versus debulking
Ester Paulien Olthof, Hans Wenzel, Jacobus van der Velden, Anje M Spijkerboer, Ruud Bekkers, Jogchum J Beltman, Hans W Nijman, Brigitte Slangen, Ramon Smolders, Nienke van Trommel, Petra L M Zusterzeel, Ronald Zweemer, Lukas J A Stalpers, Maaike van der A
International Journal of Gynecologic Cancer.2022; 32(7): 861. CrossRef
Targetability of cervical cancer by magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU)-mediated hyperthermia (HT) for patients receiving radiation therapy
Lifei Zhu, Yi Huang, Dao Lam, H. Michael Gach, Imran Zoberi, Dennis E. Hallahan, Perry W. Grigsby, Hong Chen, Michael B. Altman
International Journal of Hyperthermia.2021; 38(1): 498. CrossRef
Surgical versus clinical staging prior to primary chemoradiation in patients with cervical cancer FIGO stages IIB–IVA: oncologic results of a prospective randomized international multicenter (Uterus-11) intergroup study
Simone Marnitz, Audrey Tieko Tsunoda, Peter Martus, Marcelo Vieira, Renato Jose Affonso Junior, João Nunes, Volker Budach, Hermann Hertel, Alexander Mustea, Jalid Sehouli, Jens-Peter Scharf, Uwe Ulrich, Andreas Ebert, Iris Piwonski, Christhardt Kohler
International Journal of Gynecologic Cancer.2020; 30(12): 1855. CrossRef

First
Prev
Page of 1
Next
Last

Search